Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 5, 1998, Pages 443-448

  Dati, Francesco ^a   Pelzer, Hermann ^a   Wagner, Carola ^a  

^a Dade Behring   (Germany)

Author keywords

Hypercoagulability; Markers of hemostasis activation; Pediatrics; Pregnancy; Thromboembolism

Indexed keywords

ANTITHROMBIN III; FIBRIN MONOMER; FIBRINOGEN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOPHILIA;

EID: 0031728915     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996037     Document Type: Conference Paper

References (42)

1. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806
2. Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: A review. Semin Thromb Hemostas 1944;20:109-132
3. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993;117:17-77
4. Bauer KA, Rosenberg RD. Activation markers of coagulation. Bailliéres Clin Haematol 1994;7:523-540
5. Farced J, Bick RL, Hoppensteadt DA, Bennes EW. Molecular markers of hemostatic activation: Applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thromb/Hemostas 1995;1:87-102
6. Ofusu FA. Molecular markers of in vivo coagulation and thrombosis. In: Poller L (ed): Recent Advances in Blood Coagulation No. 6, 1993. Edinburgh: Churchill Livingstone; 51-68
7. Bruhn HD. Pathophysiology and diagnosis of prethrombosis. Lab Med 1993;17:158-164
8. Hassouna HI. Laboratory evaluation of hemostatic disorders. Hematol/Oncol Clin North Am 1993;7:1161-1249
9. Bredbacka S, Blombäck M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): New aspects. Acta Anaesthesiol Scand 1992;36:128-133
10. Hock JA, Sturk A, ten Cate JW, Lamping RJ, Berends F, Born JJ. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988;34:2058-2062
11. Pelzer H, Pilgrim A, Schwarz A, Merle D, Keuper H, Hock H. Determination of α2-antiplasmin-plasmin complex in human plasma with an enzyme-linked immunosorbent assay. Fibrinolysis 1993;7:69-74
12. Pelzer H, Schwarz A, Stueber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991;65:153-159
13. Bruhn HD, Conard J, Mannucci M, et al. Multicentric evaluation of a new assay for prothrombin fragment F 1+2 determination. Thromb Haemostas 1992;68:413-417
14. Amelsberg A, Zuborn KH, Gärtner V, Kiehne KH, Preuβe AK, Bruhn HD. Influence of heparin treatment on biochemical markers of an activation of the coagulation system. Thromb Res 1992;66:121-131
15. Bruhn HD, Liebsch J, Wagner C. Documentation of hypercoagulability by measurement of prothrombin fragment F 1+2 when introducing oral anticoagulant therapy. Thromb Res 1992;68: 317-319
16. Takahashi H, Wada K, Satoh N, et al. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1+2. Blood Coag Fibrinolysis 1993;4:435-439
17. Alving BM. The hypercoagulable states. Hosp Pract 1993;28: 109-121
18. Mammen EF, Fujii Y. Hypercoagulable states. Lab Med 1989; 20:611-616
19. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989;87(Suppl 3 B):53S-60S
20. Hopmeier P. The clinical significance of a deficiency in antithrombin III, protein C or protein S. Lab Med 1993;17:277-288
21. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation, dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemostas 1989;15:58-87
22. Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Haemostasis 1992;22:179-186
23. Roberts JM. Preeclampsia: Not simply pregnancy-induced hypertension. Hosp Pract 1995;30:25-36
24. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Gynecol Obstet Invest 1987;24:170-178
25. Bick RL. Disseminated intravascular coagulation: Objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thromb/Hemoslas 1995;1:3-23
26. Schmaier AH. Disseminated intravascular coagulation: Pathogenesis and management. J Intensive Care Med 1991;6:209-228
27. Cadroy Y, Grandjeau H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993;100:416-420
28. Von Felten A. Prophylactic heparin-treatment in pregnant women with a high risk for thromboembolism-circulation thrombin-antithrombin III (TAT) complexes as criteria for onset of treatment and dose adjustment. Therapeut Umschau 1992;49:837-842
29. Ries M, Klinge J, Rauch R, Zenker M, Aydin I, Harms D. Activation markers of the clotting and fibrinolytic system in newborn. Klin Pädiatr 1996;208:350-354
30. Schmidt B, Vegh P, Weitz J, Johnston M, Caco C, Roberts R. Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. Am Rev Respir Dis 1992;145: 767-770
31. Brus F, van Oeveren W, Okken A, Oetmo SB. Activation of the plasma clotting, fibrinolytic and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome. Pediatr Res 1994;36:647-653
32. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis. Blood Coag Fibrinolysis 1993;4:249-254
33. Garcia-Avello A, Garcia-Frade LJ, Gandarias C, Ocana J, Cancelas JA, Lasso M. High F 1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res 1994; 73:109-115
34. Szeczeklik A, Dropinski J, Radwan J, Krazanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992;12:548-553
35. Biasucci LM, Meijer P, Liuzzo G, Scabbia EV, Maseri A, Kluft C. Thrombin-antithrombin III complexes during thrombolytic therapy with rt-PA in acute myocardial infarction. Fibrinolysis 1992;3 (Suppl):71-72
36. Gulba DC, Dansel WG, Simon R, et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990;16:563-568
37. Takano K, Iino K, Ibayashi S, Tagawa K, Sadoshima S, Fujishima M. Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. Am J Cardiol 1994;74:935-939
38. Van Wersch JWJ, van Mourik-Alderliesten CH, Coremans A. Comparison of markers of coagulation activation in patients under oral anticoagulation at different levels. Eur J Clin Chem Clin Biochem 1992;30:461-466
39. Brack MJ, Hubner PJB, Gershlich AH. Anticoagulation after intracoronary stent insertion. Br Heart J 1994;72:294-296
40. Wada H, Minamikawa K, Wakita Y, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993;43:190-194
41. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993;103:196-200
42. Biasucci LM, Liuzzo G, Monaco C, et al. Plasmin-antiplasmin complexes in prognostic evaluation of patients with unstable angina. Fibrinolysis 1994;2 (Suppl.):126-127